C
카나프테라퓨틱스
0082N0KOSDAQ51.0 / 100
Reference Date: 2026-10-23
Financial Score20.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 12.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Canapharmaceuticals is an innovative biopharmaceutical company developing novel drugs for oncology and ophthalmic diseases using human genome-based technology. The company has a diverse pipeline of seven projects, including bispecific antibodies, ADCs, and synthetic drugs, and has secured significant revenue through early-stage technology transfers and co-development partnerships with major pharmaceutical firms in South Korea.
Number of Employees
23people
Average Salary
55.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
10.90Industry Average 1.200.0Point
9.1x industry avg (risky)
ROE
—Industry Average 8.003.5Point
Debt Ratio
5.73Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
2.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (2%, downtrend)
Current 10,140Won52-week high 52,20052-week low 9,240
1-month return1.0Point
1m -12.59% (falling)
Volume trend6.0Point
Volume surge
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral주식매수선택권부여에관한신고2026-10-22
- Neutral기업설명회(IR)개최2026-10-12